Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome
Open Access
- 1 March 2002
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 99 (5) , 1853-1856
- https://doi.org/10.1182/blood.v99.5.1853
Abstract
Multiparametric immunophenotyping can be a sensitive method for analyzing the plasma cell (PC) compartment in patients with multiple myeloma because it discriminates between myelomatous and normal PCs. Using this approach, we compared the efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) with that of conventional chemotherapy. We found that ASCT provided a significantly greater reduction in the level of residual tumor PCs and with better recovery of normal PCs. This profile of coexistence of normal PCs and myelomatous PCs resembled that observed in monoclonal gammopathy of undetermined significance. We also found that treatment-induced changes in the PC compartment correlated with disease outcome. Thus, patients in whom at least 30% of gated PCs had a normal phenotype after treatment had a significantly longer progression-free survival (60 ± 6 months versus 34 ± 12 months;P = .02).Keywords
This publication has 12 references indexed in Scilit:
- High-dose therapy and innovative approaches to treatment of multiple myelomaSeminars in Hematology, 2001
- B7-2–positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapyBlood, 2000
- High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myelomaBritish Journal of Haematology, 1999
- Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its ManifestationsBlood, 1998
- Circulating plasma cells in multiple myeloma: characterization and correlation with disease stageBritish Journal of Haematology, 1997
- Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple MyelomaBlood, 1997
- Expression of the CD117 antigen (C‐Kit) on normal and myelomatous plasma cellsBritish Journal of Haematology, 1996
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.Journal of Clinical Oncology, 1993
- Phenotypic difference of normal plasma cells from mature myeloma cellsBlood, 1993